Wild-type transthyretin amyloidosis (ATTRwt), an underappreciated cause of heart failure in older adults, is challenging to diagnose and monitor in the absence of validated, disease-specific biomarkers. We examined the prognostic use and survival association of serum TTR (transthyretin) concentration in ATTRwt.
W
ild-type transthyretin amyloidosis (ATTRwt) is a sporadic, fatal protein misfolding disease characterized by extracellular cardiac deposition of ordered fibrils composed of wild-type TTR (transthyretin). [1] [2] [3] [4] Formerly known as prealbumin, TTR is a liver-secreted plasma protein that functions as a minor carrier of thyroxine and binding partner to RBP4 (retinol-binding protein 4). 5, 6 Serum concentrations, normally 18 to 45 mg/dL, 7 are dependent on age, sex, race, and nutritional status; moreover, TTR levels can fluctuate as a consequence of infection or generalized inflammatory states. [8] [9] [10] Several studies have shown significantly decreased TTR concentrations in inherited forms of TTR amyloidosis (ATTRm) and lower-range normal levels in a single small ATTRwt series. 8, [11] [12] [13] ATTRwt is most commonly diagnosed in older adults with cardiomyopathy and typical heart failure symptoms [1] [2] [3] 14 ; median survival from onset of symptoms is reportedly <5 years. 15 Although prevalence in the general population is unknown, ATTRwt cardiomyopathy is likely under-recognized because the clinical features overlap with other forms of cardiac amyloid and can mimic cardiac pathologies that frequently coexist in advanced age, such as hypertensive or hypertrophic heart diseases. [16] [17] [18] [19] [20] Several studies demonstrated the presence of TTR amyloid fibrils in 10% to 25% of postmortem hearts from individuals >80 years of age, suggesting that ATTRwt may be an underappreciated cause of heart failure in older white men with diastolic dysfunction. 2, 21, 22 Accurate diagnosis of ATTRwt can be challenging because obtaining a biopsy from the affected tissue for histological evidence, the goldstandard in amyloid testing, can pose significant risk in elderly patients. Moreover, in the absence of biopsy proof, disease identification depends on appropriate interpretation of echocardiography, cardiac magnetic imaging, or nuclear scintigraphy. 23 Serum markers of myocardial damage, such as cTn-I (cardiac troponin I) and BNP (B-type natriuretic peptide), have been used to support a diagnosis of ATTRwt and measure worsening cardiac status, but no definitive biomarkers of disease have been identified. 24 Treatment of ATTRwt has previously been confined to cardiac transplantation; however, there are currently many investigational agents in clinical trial that may halt TTR amyloid deposition and extend survival. One of these agents, diflunisal, stabilizes tetrameric TTR and inhibits misfolding 25 ; diflunisal is reportedly effective for neuropathy associated with ATTRm and, by extension, is being used clinically in selected patients with ATTRwt. 26 The complexities of the diagnostic algorithm, absence of disease-specific measures of progression, and lack of consensus on risk predictors demand the development of ATTRwt biomarkers to facilitate diagnosis and disease monitoring. The goal of this study was to evaluate the use of serum TTR concentration as a marker of ATTRwt and to determine its prognostic value for overall survival.
METHODS
The data that support the findings of this study are available from the corresponding author on reasonable request.
Study Groups
Deidentified serum samples and data from patients with ATTRwt were obtained from the Boston University Amyloidosis Center specimen repository and clinical database with written consent under approval of the Institutional Review Board at the Boston University Medical Campus in accordance with the Declaration of Helsinki. Clinical data included details of history, physical examination, laboratory testing, and echocardiographic studies. Patients were selected from an ongoing longitudinal ATTRwt cohort evaluated at our center between January 2009 and December 2016 (Figure 1 ). Diagnosis of ATTRwt was based on biopsy proof of amyloid by Congo red staining and biochemical or immunochemical proof of TTR as the major component of the amyloid deposit. Sequencing of all 4 exons of the TTR gene was performed to rule out the presence of pathological TTR mutations. Of 123 patients diagnosed with ATTRwt, 116 were included in this study; 7 were excluded for lack of adequate serum samples, incomplete clinical data for selected laboratory parameters, or because of established treatment with a TTR stabilizer at initial evaluation. For comparison of TTR concentrations at baseline, 30 control serum samples from healthy white males ≥60 years of age were purchased from Bioreclamation (Westbury, NY) and compared with an ATTRwt subgroup matched for
WHAT IS NEW?
• This report demonstrates that lowered serum TTR (transthyretin) is a risk factor associated with marked cardiac impairment, worsening disease characteristics, and decreased survival in patients with wild-type transthyretin amyloidosis.
• We present a combined model of TTR, cTn-I (cardiac troponin I), and left ventricular ejection fraction as most predictive of 4-year survival.
WHAT ARE THE CLINICAL IMPLICATIONS?
• The clinical evaluation of serum TTR levels, particularly in assessing concentrations outside the normal range, seems to be important as an individual metric, as well as in combination with other indicators of cardiac functional status.
• Stratification of patients using a threshold serum TTR concentration of 18 mg/dL may have prognostic value, and longitudinal measurement of the serum protein could potentially inform interpretation of disease course modification by diflunisal or future therapeutic interventions.
age, race, and sex (n=108). In addition, ATTRwt baseline values were also compared with serum TTR levels measured in a small group (n=9) of matched patients with cardiomyopathy unrelated to amyloid. Survival analyses were conducted on 101 of 116 patients excluding those who were receiving TTRstabilizing treatments at initial or follow-up evaluations: 12 were being treated with diflunisal and 3 were in clinical trials for tafamidis. 27 A 1-year follow-up evaluation included 23 untreated patients and 12 patients treated with the TTR stabilizer, diflunisal, started after the initial visit. A 2-year follow-up evaluation included 10 untreated patients and 5 treated with diflunisal for the entire follow-up.
Clinical, laboratory, and echocardiographic data were chosen based on our previous report detailing the natural history of ATTRwt. 15 Serum concentrations of cTn-I, BNP, total protein, albumin, creatinine, uric acid, CRP (C-reactive protein), or sensitive CRP and sedimentation rate were measured as part of routine laboratory testing. The CRP and sensitive CRP values were converted to dichotomous variables (normal range thresholds, <1 mg/dL and ≤5 mg/L, respectively) because measurements for each variable were not available in all patients. Echocardiographic parameters including interventricular septal thickness, left ventricular ejection fraction (LVEF), left ventricular mass index, and relative wall thickness were derived by researchers blinded to patient diagnosis as described. 15 
Serum TTR Measurements
Serum TTR concentrations were measured by the Boston Medical Center Pathology Department using a Clinical Laboratory Improvement Amendments-approved immunoturbidimetric assay for prealbumin with coefficients of variation <5.5% (Abbott Laboratories, Abbott Park, IL). Serum samples were assessed immediately or stored at ≤−20°C before analysis. Freezer temperature and freeze/thaw cycles had no effect on TTR concentration.
Statistical Analysis
Data describing initial and follow-up evaluations including baseline characteristics, plots, and associated P values were generated using GraphPad Prism software, version 5.02 (La Jolla, CA). Deviations from normal distribution were assessed using the Shapiro-Wilk test. P values comparing treated and untreated groups were determined by unpaired, two-sided t test with Welch correction or Mann-Whitney test, depending on data normality. P values comparing within-group followups were determined by paired, 2-sided t test or Wilcoxon signed-rank test. All t tests were performed with a type I error rate set at α=0.05.
Survival analyses were performed using R Foundation for Statistical Computing software, version 3.2.3 (Vienna, Austria). TTR, serological, and echocardiographic variables were examined for associations with overall survival (OS). Univariate Cox analysis was initially performed to identify factors associated with OS and subsequently adjusted for age, body mass index (BMI), and New York Heart Association class at the time of presentation. All univariate variables with P<0.1 were included in a multivariate proportional hazards regression model, and P<0.05 was considered statistically significant. The sensitivities, specificities, and area under the receiver-operating characteristic curve at 4 years were calculated using the nearest neighborhood estimator approach by Heagerty et al 28 accounting for censoring in survival data.
OS curves were estimated by the Kaplan-Meier method and compared using a log-rank test. The lower normal limit of 18 mg/dL TTR 7 was used as a threshold to stratify patients. Survival time was measured from date of positive biopsy (diagnosis) to death. Follow-up ended in December 2016, and patients who survived beyond the study period were censored.
RESULTS

ATTRwt Cohort Characteristics
Baseline clinical, laboratory, and echocardiographic features in 116 patients with ATTRwt are shown in Table 1 . The median age at baseline was 76.0 years (range, 51.0-87.8 years; Table 1 ). The majority were male (97.4%) and white (96.5%). Three women exhibited similar characteristics to the remainder of the cohort with respect to age, serological testing, and echocar- with adequate repository samples and complete laboratory data were included in baseline studies. Of these, 108 were white males over 60 years of age, to be matched to the control group; and, 101 were not treated with transthyretin (TTR) stabilizers throughout their follow-up period. The 3 baseline groups in tier 2 were used for certain analyses, identified by italic font in each box. Thirty-five patients were evaluated at 1 y: 23 received no treatment, and 12 were treated with diflunisal. Fifteen patients were evaluated at 2 y: 10 untreated and 5 diflunisal treated. diographic measures. Wild-type TTR coding region sequences were identified in all cases, with the exception of nonpathological G6S (p.G26S), identified in 6 out of 116 (5.2%) of the group. Consistent with our previous report, 15 abdominal fat biopsy documented amyloid in 21.5% of patients. BMI was slightly elevated at 28.2 kg/m 2 (range, 22.0-38.2 kg/m 2 ). Median serum TTR level at presentation was 23 mg/ dL, ranging from 11 to 39 mg/dL (Table 1) ; moreover, a study of sera from ATTRwt and age-, sex-, and racematched healthy and nonamyloid cardiomyopathy controls showed comparable TTR concentrations in all groups (23 versus 24 and 25 mg/dL; P=0.109 and 0.484, respectively; Figure I in the Data Supplement). In ATTRwt, median values for total protein, albumin, sedimentation rate, and creatinine were within normal ranges. CRP was abnormal in 24.1% (Table 1) . Median values for serological and echocardiographic markers of cardiac function, cTn-I, BNP, interventricular septal thickness, relative wall thickness, LVEF, and left ventricular mass index were outside the normal range and reflected cardiac involvement (Table 1) . A majority (81%) of patients presented with New York Heart Association functional class of ≥II, and 68.1% showed evidence of arrhythmia by electrocardiography at baseline.
Overall Survival and Factors Associated With Survival
At the end of observation, 53 of 116 patients (45.7%) had died with a median time from diagnosis to death of 3.1 years (range, 0.1-7.3 years). The estimated median OS for the entire ATTRwt cohort (n=116) was 4.0 years (95% confidence interval, 3.6-5.4 years) and for untreated patients (n=101), 3.9 years (range, 3.5-4.8 years); no treated patients had died by the end of observation. Parameters associated with OS in univariate analysis of untreated patients included TTR (P=0.007), cTn-I (P<0.001), BNP (P=0.002), LVEF (P=0.001), creatinine (P=0.02), uric acid (P=0.02), and sedimentation rate (P=0.001; Table 2 ). Multivariate analysis yielded TTR (P<0.001), cTn-I (P<0.001), and LVEF (P=0.01) as indicators of shorter survival. No significant multicollinearity was observed; adjustment for baseline factors, age, BNP, and New York Heart Association class did not affect these results. Hazard ratios for TTR obtained when controlling for several baseline variables were as Uric acid, mg/dL 7.9 (6.0-9. The value of single or multiple variables in predicting 4-year survival was assessed using receiver-operating characteristic analysis (Figure 2) . Individually, the area under the curve values indicated that sensitivity was comparable for TTR (0.69), cTn-I (0.60), and LVEF (0.64). However, an inclusive model that used all 3 factors rendered the greatest power (0.77). The 4-year receiver-operating characteristic analysis was selected a priori because ATTRwt OS was 4 years; reported 4-year area under the curve values were similar for 3-and 5-year analyses (Table I in the Data Supplement).
To further examine the association of TTR with OS, untreated patients were stratified by the lower normal limit of circulating TTR, 18 mg/dL ( Figure 3 ). Patients with baseline TTR ≥18 mg/dL had a median survival time of 4.1 years (95% confidence interval, 3.6-5.5 years) versus 2.8 years (95% confidence interval, 1.4-4.0 years) in the group with TTR below the threshold value (P=0.03; hazard ratio, 2.3; 95% confidence interval, 1.2-4.3).
Longitudinal Analyses in ATTRwt
Cardiac and renal functional status markers at baseline were superior in the diflunisal-treated patients compared with those not taking the drug. However, median TTR concentrations in both groups at baseline were similar (24 versus 23 mg/dL; P=0.466).
At 1-year evaluations of untreated and treated patients, values for 2 of 3 OS predictors, TTR and cTn-I, were significantly worse in the untreated group by a between-group analysis of median values (Table 3) . Moreover, differences between the groups were maintained for both markers: TTR (20 versus 31 mg/ dL; P<0.001) and cTn-I (0.126 versus 0.064 ng/mL; P=0.003) at 2-year follow-up. Within the untreated and treated patient groups, TTR, cTn-I, and LVEF were assessed over the interval from baseline to 2-year follow-up, and differences were noted for TTR and cTn-I (Figure 4 ; Figure II in the Data Supplement). In the untreated group, cTn-I significantly increased when measured longitudinally from baseline to 2-year evaluation (P=0.006); there were also significant increases incrementally from baseline to 1 year (P=0.022) and 1 to 2 years (P=0.041) evaluations. In contrast, the diflunisal-treated group featured substantially increased TTR at 1-year evaluation compared with baseline (P=0.001), which persisted through 2-year follow-up; these results paralleled stable levels of cTn-I at 1-year (P=0.266) and 2-year follow-ups (P=0.583). 
DISCUSSION
This is the first report to detail the results of a crosssectional and longitudinal study of serum TTR concentrations and analysis of TTR as a risk predictor in a large series of patients with biopsy-proven ATTRwt cardiac amyloidosis. Serum TTR was examined along with 14 other serological measures and echocardiographic parameters to ascertain associations with survival; in addition, TTR concentrations at 1-year and 2-year follow-up evaluations were compared in diflunisal-treated and untreated ATTRwt patients. Major aspects of this study include (1) confirmation that serum TTR concentrations in ATTRwt at diagnosis are near the lower limit of normal range, (2) establishment of serum TTR as a significant prognostic determinant in ATTRwt, (3) presentation of an inclusive model for predicting outcome using TTR, cTn-I, and LVEF, and (4) demonstration that diflunisal treatment coincided with significant increases in serum TTR concentration and was associated with improving cardiac status during 2-year follow-up.
Key Findings and Clinical Implications
Serum TTR concentrations in patients with ATTRwt were in the lower, normal range and comparable to matched, healthy controls; this finding was in agreement with a previous report in a smaller series. 8 Importantly, in this first study of TTR as a mortality indicator and predictor of outcome in ATTRwt amyloid disease, our data showed a significant association between lower levels of TTR and shorter survival, as well as a correlation to worsening cardiac disease, suggesting that TTR concentration is an indicator of disease progression and outcome in ATTRwt. We provide evidence that, despite biological associations with age, race, sex, nutritional status, and inflammatory state, TTR has use as a metric in ATTRwt and together with current cardiac function status markers can provide sensitive and specific monitoring of disease progression, response to treatment, and disease risk assessment. Although in this study, TTR correlated with CRP, sedimentation rate, and albumin, all markers of inflammation, no significant multicollinearity was observed between TTR and any markers of inflammation or nutrition; any relationship of TTR to these factors had no effect on the Cox analysis. Because quantification of TTR (frequently referred to as prealbumin testing) is routinely performed and commonly available in most clinical laboratories, measurement of this serum protein could readily be included in patient evaluation. Our findings and the availability of testing suggest that serum TTR concentration is a plausible metric of progression and outcome in ATTRwt disease.
More specifically, a serum TTR concentration of 18 mg/dL likely has potential use as a threshold value in risk predictions. In the stratification of untreated patients at baseline using the 18 mg/dL threshold, we found that lower TTR was associated with poorer survival, as well as significantly higher BNP (P=0.038). Moreover, in the follow-up analyses, patients exhibited worsening cardiac status temporally concomitant with declining TTR values that were lower than those who had been treated. Although the untreated follow-up group represented patients who were more ill and unable to tolerate the NSAID, diflunisal, it is important to note that progression of disease was only observed in the untreated group; in contrast, cardiac status remained stable in the treated group. Because diflunisal treatment coincided with both higher TTR and stabilized cardiac function, we ruled out drug effect in the survival analyses by limiting the group to patients who had never received TTR-stabilizing treatment. Small group numbers precluded statistical adjustment to eliminate data skewing for baseline healthstatus confounders; however, our conclusions were supported in a subanalysis pairing of treated/untreated patients matched for baseline TTR, age, BMI, uric acid, and cTn-I (within 4 mg/dL, 5.1 years, 4 kg/m 2 , 2.1 mg/ dL, and 0.06 ng/mL, respectively) and with normal CRP. Results showed declining TTR values and worsening disease characteristics in the untreated group, whereas the treated patients exhibited increasing TTR and corresponding declining cardiac status markers (Table II in the Data Supplement). Despite small follow-up group numbers, our results indicate that TTR has prognostic use and suggest that lowered TTR concentration corresponds to progression of cardiac amyloidosis.
The longitudinal data provide evidence that diflunisal treatment corresponded to increasing TTR concentration. Furthermore, OS was observed to increase in the total cohort including diflunisal-treated patients (n=113; OS 4.7 versus 4.1 years); these results suggest that patients receiving the TTR-stabilizing drug, albeit a small number (12 versus 101) compared with the untreated group, may have extended survival. Of note, cardiac biomarkers were lower in diflunisaltreated patients reflecting a lower end-organ amyloid burden. On the basis of the TTR tetramer-stabilizing effect of diflunisal predicted by in vitro experiments, 25 the observed TTR increase with diflunisal treatment likely signals effective TTR stabilization and protection from renal clearance. Molecular stabilization of TTR by diflunisal has been shown to halt or slow neurological disease progression in patients with ATTRm
26
; however, the effect of diflunisal in ATTRwt is yet to be studied systematically. Undetermined is whether total TTR concentration or tetramer stabilization at presentation is specifically linked to better prognosis, or whether increases in TTR concentration or initially higher TTR levels at disease onset is beneficial.
Prior Studies
The present investigation is an extension of our previously reported prospective, observational cohort study that documented the natural history of ATTRwt in a large series and identified BNP, relative wall thickness, LVEF, and uric acid as factors associated with survival. 15 Although there was overlap in the patient groups used in the present and previous studies, the initial report by Connors et al did not include TTR in the evaluation of serological parameters in the ATTRwt series collected between 1994 and 2014, whereas the current study was restricted to patients with serum samples available for TTR quantification and evaluated from 2009 to 2016. In this recent analysis, multivariate testing identified reduced TTR and LVEF and increased cTn-I as factors associated with worsening prognosis. These data add the predictive value of TTR to previous findings showing the prognostic value of cardiac measures. We consistently identified LVEF as a risk predictor, though our prior study found elevated BNP to be an indicator of reduced survival, whereas the current analysis identified cTn-I as more significantly associated with outcome. It is not surprising that only one cardiac biomarker was present in each reported Cox model; this likely results from statistical overlap or may be because of the large range of BNP values represented in the present study, which may obscure recognition of a survival association. Of note, atrial fibrillation was the most frequent arrhythmia in this study, as established previously. 15 Grogan et al 19 from the Mayo Clinic proposed a staging system for ATTRwt based on cTn-T and NT-proBNP (N-terminal B-type natriuretic peptide) measurements and 2 related cardiac biomarkers not routinely measured at our center during the study period. These parameters were selected based on a similar Cox model analysis, in which age, LVEF, N-terminal B-type natriuretic peptide, and cardiac troponin T were identified as multivariate risk factors for ATTRwt. Differences among the reports may stem from the list of tested variables; although our analyses did not include cTn-T and NT-proBNP, the study by Grogan et al did not assess TTR and cTn-I. Nonetheless, the similarities in results between our 2 studies can be seen, in part, as external validation. In the Transthyretin Amyloid Outcomes Survey, 29 BNP and cTn-I were significantly elevated, whereas high cTn-T was associated with decreased survival in a report by Pinney et al 30 Most recently, a study by Arvanitis et al 31 used a similar analysis of potential serological factors for early identification of patients with ATTRm V122I. Markers tested included TTR, RBP4, and indicators of cardiac damage, with RBP4 associating with ATTRm V122I disease expression. The association of TTR and RBP4, previous findings of lowered TTR levels in ATTRm, and the results of the current and most recent reports, all suggest that a deeper understanding of the relationship of serum TTR and RBP4 levels in ATTR-related cardiac diseases is warranted. Importantly, several biomarkers of myocardial damage have been consistently identified as disease-asso-ciated prognostic risk factors by our group and others. Because the current study was the only one to consider TTR concentration, further investigation is necessary to confirm the use of TTR as a specific marker of ATTRwt. Additionally, a combination of TTR and certain cardiac function measures may yield the most accurate survival prediction model in ATTRwt cardiac amyloidosis. Yet to be established, potentially through multicenter collaboration, is the combination of determinants that yield the greatest value as disease-specific indicators and accuracy as predictors of outcome in ATTRwt.
Study Limitations
Several limitations of our study should be considered. The examination of a relatively small cohort of patients is a limitation because small group numbers typically yield low-powered studies; however, this is the first report demonstrating the value of TTR, a serum protein routinely tested in clinical laboratories, as a potential ATTRwt disease marker. In addition, data from the survival analyses presented high levels of significance. Although a staging system has not been proposed, we anticipate that the ever-expanding series of patients with ATTRwt evaluated at our center will confirm the importance of TTR concentration and provide a validation group for model testing in the future. Additionally, our study did not include echocardiographic strain, cardiac magnetic resonance imaging, nuclear imaging data, and N-terminal B-type natriuretic peptide measurements currently considered to be important in monitoring patients with ATTRwt cardiac amyloid disease. 2, 23 Many of the aforementioned metrics were unavailable on patients included in this series because of the retrospective nature of the study; furthermore, the small number of patients with data for some measures precluded inclusion in our analysis. Finally, the biochemical nature of the TTR (tetramer, monomer, and oligomer) that is quantified by antibody recognition in the immunoturbidimetric assay is unknown. Whether a continuous decrease in specific amyloid-related or total circulating levels of TTR occurs during ATTRwt disease progression is yet to be determined; further studies may help to elucidate the mechanistic contributions of TTR gene expression, serum concentration, and fibril deposition in this disease.
Conclusions
In this first report that identifies TTR concentration as an independent predictor of OS in ATTRwt, we present an inclusive model combining 3 factors (TTR, cTn-I, and LVEF) with high prognostic accuracy. Moreover, patients with TTR in the normal range (≥18 mg/dL) exhibited significantly better OS (4.1 years) compared with those with low TTR (<18 mg/dL; OS 2.8 years), suggesting the use of 18 mg/dL as a threshold value in risk assessment. Furthermore, we provide preliminary evidence that treatment with the TTR stabilizer, diflunisal, results in increased TTR concentration and stabilized cTn-I and LVEF over a 2-year period, indicating a delay in progression of ATTRwt symptoms. In contrast, untreated patients exhibited persistently low TTR concentrations corresponding to worsening cardiac disease as represented by increasing cTn-I. These data suggest that TTR serum concentration at presentation predicts survival in patients with ATTRwt, whereas serial TTR measurements provide an indication of disease progression.
